How does the efficacy of tigecycline's generic injection compare to the brand name in clinical trials?

Short answer: There aren’t published head-to-head clinical trials comparing brand-name tigecycline (Tygacil) with its generic injections. Generics are approved based on demonstrating bioequivalence and pharmaceutical equivalence to the brand-name product, not by separate efficacy trials.

What that means in practice:
- Generics must have the same active ingredient, strength, dosage form, and route of administration (pharmaceutical equivalence).
- They must be bioequivalent to the brand product. For IV antibiotics like tigecycline, this is shown by pharmacokinetic studies (e.g., AUC and Cmax) with the 90% confidence interval for the generic/brand comparison typically falling within 80%–125%.
- If bioequivalence is proven, regulatory agencies (e.g., FDA in the U.S.) consider the generic to have no clinically meaningful difference in efficacy or safety compared with the brand-name product. No separate efficacy trial is generally required or expected.

What you can check if you want specifics:
- Look up the drug in the FDA Orange Book to verify bioequivalence status (an “A” rating indicates BE with the brand-name product).
- Review the labeling for the specific generic product and compare with the brand labeling for the same indications, dosage, and warnings.

If you’re evaluating a particular generic product, I can help look up its BE status or summarize the labeling. Note also that tigecycline carries safety considerations (e.g., boxed warnings about mortality risk in certain uses) that apply regardless of whether the product is brand-name or generic.